Daprodustat

产品说明书

Print
Chemical Structure| 960539-70-2 同义名 : GSK1278863
CAS号 : 960539-70-2
货号 : A166874
分子式 : C19H27N3O6
纯度 : 98+%
分子量 : 393.43
MDL号 : MFCD29924726
存储条件:

Pure form Sealed in dry, room temperature

In solvent -20°C:3-6个月-80°C:12个月

溶解度 :

DMSO: 18 mg/mL(45.75 mM),配合低频超声,并水浴加热至45℃助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

动物实验配方:
生物活性
靶点
  • PHD1

描述 The family of HIF-PH (HIF prolyl hydroxylase) enzymes are the main molecular to regulate HIF activity through hydroxylation at 2 proline residues and cause the degradation of HIF, thus leading to inhibition on accumulation of functional HIF under normoxia. Daprodustat is a potent HIF-PH with IC50 values of 3.5 nM, 22.2 nM and 5.5 nM for PHD1, PHD2 and PHD3 (measured by FRET), respectively. Treatment with either 25 or 50 μM Daprodustat for 6h resulted in the accumulation of both HIF1α and HIF2α subunits in nuclear protein extracts of Hep3B cells. A single oral dose of GSK1278863 at 60 mg/kg resulted in EPO protein levels peaked at 12 hours post-dose, representing an 11.2-fold increase with a mean plasma concentration of 1303 pg/mL with minimal impact on VEGF concentrations in normal female B6D2F1 mice. Repeated daily treatment of normal B6D2F1 mice with Daprodustat at dose of 3, 10, or 30 mg/kg for 8 days, resulted in significant increases in reticulocytes, hemoglobin levels as well as red blood cell counts and hematocrit[1]. Up to now, a phase 3 study to evaluate efficacy and safety of Daprodustat compared to Darbepoetin Alfa in Japanese Hemodialysis (HD)-Dependent Subjects with Anemia Associated with Chronic Kidney Disease (CKD) has been completed(see https://clinicaltrials.gov/).
作用机制 Daprodustat can form tight binding interactions with the catalytic iron and a co-factor-pocket arginine residue of PHD.
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

2.54mL

0.51mL

0.25mL

12.71mL

2.54mL

1.27mL

25.42mL

5.08mL

2.54mL

参考文献

[1]Ariazi JL, Duffy KJ, et al. Discovery and Preclinical Characterization of GSK1278863 (Daprodustat), a Small Molecule Hypoxia Inducible Factor-Prolyl Hydroxylase Inhibitor for Anemia. J Pharmacol Exp Ther. 2017 Dec;363(3):336-347.